We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Corcept Therapeutics Inc (CORT) Common Stock USD0.001

Sell:$50.00 Buy:$57.00 Change: $0.25 (0.49%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$50.00
Buy:$57.00
Change: $0.25 (0.49%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$50.00
Buy:$57.00
Change: $0.25 (0.49%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

Contact details

Address:
101 REDWOOD SHORES PARKWAY
REDWOOD CITY
94065
United States
Telephone:
+1 (650) 6888803
Website:
https://www.corcept.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CORT
ISIN:
US2183521028
Market cap:
$5.49 billion
Shares in issue:
104.78 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Joseph Belanoff
    President, Chief Executive Officer, Co-Founder, Director
  • Atabak Mokari
    Chief Financial Officer, Treasurer
  • Sean Maduck
    President - Corcept Endocrinology
  • Roberto Vieira
    President - Oncology
  • Joseph Lyon
    Chief Technology Officer, Chief Accounting Officer
  • Hazel Hunt
    Chief Scientific Officer
  • William Guyer
    Chief Development Officer
  • Gary Robb
    Chief Business Officer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.